^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

sabutoclax (ONT-701)

i
Other names: ONT-701, BI-97C1
Associations
Trials
Company:
Pfizer, Sanford-Burnham Medical Research Institute
Drug class:
Bcl2 inhibitor, Bcl-xL inhibitor, MCL1 inhibitor
Related drugs:
Associations
Trials
22d
Explore the expression of mitochondria-related genes to construct prognostic risk model for ovarian cancer and validate it, so as to provide optimized treatment for ovarian cancer. (PubMed, Front Immunol)
In terms of drug sensitivity, the high-risk group was more sensitive to vinblastine, Acetalax, VX-11e, and PD-0325901, while the low-risk group was more sensitive to Sabutoclax, SB-505124, cisplatin, and erlotinib. The prognostic risk model of ovarian cancer associated to mitochondrial genes built on the basis of public database better evaluated the prognosis of ovarian cancer patients and guided individual treatment.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
cisplatin • erlotinib • mirdametinib (PD-0325901) • VTX-11e • vinblastine • sabutoclax (ONT-701)
3ms
Establishment of a prognostic model for pancreatic cancer based on mitochondrial metabolism related genes. (PubMed, Discov Oncol)
By utilizing a gene signature associated with mitochondrial metabolism, a prognostic model has been established which could be a highly efficient method for predicting the outcomes of PAAD patients.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
|
Venclexta (venetoclax) • sabutoclax (ONT-701)
over1year
Coordination-Driven Self-Assembly of Biomedicine to Enhance Photodynamic Therapy by Inhibiting Proteasome and Bcl-2. (PubMed, Adv Healthc Mater)
Herein, a self-delivery biomedicine (designated as BSC) is developed by the self-assembly of Bortezomib (BTZ), Sabutoclax (Sab) and Chlorin e6 (Ce6). Of special note, the coordination-driven self-assembly of BSC is pH-responsive, which could be disassembled for controlled drug release upon tumor acidic microenvironment. This study would expand the applicability of self-delivery nanomedicine with sophisticated mechanisms for tumor treatment.
Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
bortezomib • sabutoclax (ONT-701)
over1year
A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations. (PubMed, Front Surg)
Moreover, we identified SGPP1, RHOQ, and PDGFRB as potential targets for TP53-mutant COAD, and illuminated that the high-risk patients might benefit from IGFR-3801, Staurosporine, and Sabutoclax...Besides, we identified novel therapeutic targets and potential sensitive agents for TP53-mutant COAD with high risk. Our findings provided not only a new strategy for prognosis management but also new clues for drug application and precision treatment in COAD with TP53 mutations.
Journal
|
TP53 (Tumor protein P53) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
TP53 mutation • TP53 wild-type • TP53 expression • PDGFRB mutation
|
sabutoclax (ONT-701)
almost2years
Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer. (PubMed, Aging (Albany NY))
We successfully established and verified a novel circadian clock-related gene signature, which could stratify patients with different risk and be reflective of the therapeutic effect of molecular targeted therapy. Our findings could incorporate the pharmacological modulation of circadian clock into future therapeutic strategies.
Journal
|
CD8 (cluster of differentiation 8) • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • CDK1 (Cyclin-dependent kinase 1) • KLF10 (Kruppel Like Factor 10)
|
erlotinib • linsitinib (ASP7487) • foretinib (GSK1363089) • BMS-536924 • sabutoclax (ONT-701)
over3years
[VIRTUAL] REVEALING TRANSCRIPTOME DEREGULATION COMPLEXITY IN MULTIPLE MYELOMA (EMN 2021)
The SKMM2 MM cell line, harboring t(11;14), del(CYLD) was highly sensitive to Venetoclax...Of note, these latter resulted sensitive to Sabutoclax, a panBCL2-axis inhibitor... Our study showed a link between the genomic archi- tecture and transcriptome in MM, where CNAs and CRs had a stron- ger impact on expression than gene mutations. Within these lattes UPON GENOMIC HS ones need further testing as they may represent future treatment targets. Moreover, the mutational status is crucial since, due to the transcriptomic consequences of bi-allelic events which provides bio- logical basis for the observed prognostic impact of “double-hit” MM.
IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2L1 (BCL2-like 1)
|
TP53 mutation • KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600 • Chr t(11;14) • BCL2L1 overexpression • MCL1 overexpression • BCL2 expression • MCL1 expression • IGH translocation
|
Venclexta (venetoclax) • sabutoclax (ONT-701)
4years
[VIRTUAL] Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma (ASH 2020)
The SKMM2 MM cell line, harboring t(11;14), del(CYLD) e NOXAamp was highly sensitive to Venetoclax...Of note, these latter resulted sensitive to the pan-BCL2 axis inhibitor Sabutoclax...Moreover, the mutational status is crucial since, while mono-allelic events are often of little transcriptional value, compound heterozygosity carries a huge influence on transcriptomic which provides biological basis for the observed prognostic impact of “double-hit” MM. Finally, we suggest that a comprehensive profiling of the BCL2 pathway may identify biomarkers of sensitivity to BCL2 inhibitors in addition to the t(11;14).
IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1) • BCL2L1 (BCL2-like 1) • IRF4 (Interferon regulatory factor 4)
|
BRAF V600E • KRAS mutation • BRAF mutation • BRAF V600 • Chr t(11;14) • MCL1 overexpression • MCL1 expression
|
Venclexta (venetoclax) • sabutoclax (ONT-701)